Clinical cancer screening guidelines have been developed and implemented for other cancer predisposition syndromes (CPSs) such as Li Fraumeni syndrome/TP53 germline mutation carriers (LFS) and constitutional mismatch repair deficiency syndrome (CMMRD), and have potential to reduce diagnostic delays, detect malignancies at an earlier stage, allow earlier initiation of treatment and improve cancer‐related outcomes.14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24. Here, TP53 is linked to cancer.